Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy

Trial Profile

Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs Varlitinib (Primary) ; Capecitabine; Lapatinib
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors ASLAN Pharmaceuticals
  • Most Recent Events

    • 02 Jan 2018 According to an ASLAN Pharmaceuticals media release, results were presented at the ESMO Asia 2017.
    • 16 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 09 Feb 2017 Primary endpoint (Percentage change from baseline tumor size at Week 12) has been met, according to an ASLAN Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top